Abstract: A novel class of compounds according to Formula I, II, or III, wherein W1-W4, Z1-Z4, Z1-Z5, X, Y, n, and R1-R8 are as defined in the claims and description of embodiments that bind to fatty acid binding protein FABP4 and modulate adipocyte metabolism to drive enhanced glucose utilization, as well as pharmaceutical compositions comprising the class of compounds, in combination with a pharmaceutically acceptable diluent or carrier, and optionally, further in combination with a therapeutically active agent, and the use of these compounds in medicine and for the preparation of a medicament in the treatment of disorders acting on the FABP4. In examples, the ring Z contains Z1-Z4. In other examples, the ring Z contains Z1-Z5.

Abstract: A method for treating a viral disease in a subject comprising administering to said subject a therapeutically effective dose of one or more compounds that bind to fatty acid binding protein FABP4, with compounds described in the specification some having the general formula, Formula I-Formula XII, where W1-W4, Z1-Z4, Z1-Z5, X, Y, n, and R1-R8 are as defined in the claims and description of embodiments. In examples, the ring Z contains Z1-Z4. In other examples, the ring Z contains Z1-Z5.

Abstract: A method for treating a viral disease in a subject comprising administering to said subject a therapeutically effective dose of one or more compounds that bind to fatty acid binding protein FABP4, with compounds described in the specification some having the general formula, Formula I-Formula XII, where Wi - W4, Z1-Z4, Z1 - Z5, X, Y, n, and R1 - R8 are as defined in the claims and description of embodiments. In examples, the ring Z contains Z1-Z4. In other examples, the ring Z contains Z1-Z5.

Abstract: A class of compounds that bind to FABP4 and inhibit viral replication in cells, as well as pharmaceutical compositions comprising the class of compounds, in combination with a pharmaceutically acceptable diluent or carrier, and optionally, further in combination with an additional therapeutically active agent, and the use of these compounds in medicine and for the preparation of a medicament in the treatment of viral diseases.

Abstract: A class of compounds that bind to fatty acid binding protein (FABP4) and modulate adipocyte metabolism to drive enhanced glucose utilization, as well as pharmaceutical compositions comprising the class of compounds, in combination with a pharmaceutically acceptable diluent or carrier, and optionally, further in combination with a therapeutically active agent, and the use of these compounds in medicine and for the preparation of a medicament in the treatment of disorders acting on the FABP4.

Abstract: A class of compounds that bind to FABP4 and inhibit viral replication in cells, as well as pharmaceutical compositions comprising the class of compounds, in combination with a pharmaceutically acceptable diluent or carrier, and optionally, further in combination with an additional therapeutically active agent, and the use of these compounds in medicine and for the preparation of a medicament in the treatment of viral diseases.

Abstract: Novel compounds useful for treating and/or preventing HCMV infections are provided.

Abstract: Novel compounds useful for treating and/or preventing HCMV infections are provided.

Abstract: A novel class of compounds according to Formula I, II, or III, wherein W1-W4, Z1-Z4, Z1-Z5, X, Y, n, and R1-R8 are as defined in the claims and description of embodiments that bind to fatty acid binding protein FABP4 and modulate adipocyte metabolism to drive enhanced glucose utilization, as well as pharmaceutical compositions comprising the class of compounds, in combination with a pharmaceutically acceptable diluent or carrier, and optionally, further in combination with a therapeutically active agent, and the use of these compounds in medicine and for the preparation of a medicament in the treatment of disorders acting on the FABP4. In examples, the ring Z contains Z1-Z4. In other examples, the ring Z contains Z1-Z5.

Abstract: A method is provided to improve virus production is an infected host cell by culturing the infected cell in an effective amount of alpha-ketoglutarate.

Abstract: This document relates to compounds useful as agents for preventing or treating human cytomegalovirus (HCMV) infections.

Abstract: Agents and methods of inhibiting or improving the growth of viruses are provided.

Abstract: This document relates to compounds useful as agents for preventing or treating human cytomegalovirus (HCMV) infections.

Abstract: Novel compounds useful for treating and/or preventing HCMV infections are provided.

Abstract: Novel compounds useful for treating and/or preventing HCMV infections are provided.

Abstract: A method is provided to improve virus production is an infected host cell by culturing the infected cell in an effective amount of alpha-ketoglutarate.

Abstract: The present disclosure provides a method to enhance the production of virus in cultured fibroblasts by supplementing the cells with a TCA cycle intermediate, aketoglutarate, or a derivative thereof, wherein virus production is enhanced compared to the same method canied out in the absence of a-ketoglutarate or the derivative thereof. In view of the art, the method provides an unexpected improvement on methods routinely practiced.

Abstract: Novel compounds useful for treating and/or preventing HCMV infections are provided.

Abstract: This document relates to compounds useful as agents for preventing or treating human cytomegalovirus (HCMV) infections.

Abstract: Agents and methods of inhibiting or improving the growth of viruses are provided.